Search
for
Sort by
Research 151–180 of 1000+
- Investigating the roles of cellular senescence in embryogenesis and aging
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Treatment of severe alopecia areata with baricitinib
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- Application of Baricitinib in Dermatology
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
- Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
- Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Reversal of alopecia areata, osteoporosis follow treatment with activation of Tgr5 in mice
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Unexpected Effect of Baricitinib Use: Observation of a Case of Hypertrichosis
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Successful treatment of severe diffuse alopecia areata with abrocitinib
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata